Acorah Software Products - Accounts Production 19.3.600 false true 30 June 2025 1 July 2024 false 1 July 2025 30 June 2026 30 June 2026 14971954 Prapakaran Kanagaratnam Dr Nicholas Linton Dr B Temelkuran Professor E Drakakis iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 14971954 2025-06-30 14971954 2026-06-30 14971954 2025-07-01 2026-06-30 14971954 frs-core:CurrentFinancialInstruments 2026-06-30 14971954 frs-core:ComputerEquipment 2025-07-01 2026-06-30 14971954 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-07-01 2026-06-30 14971954 frs-core:FurnitureFittings 2026-06-30 14971954 frs-core:FurnitureFittings 2025-07-01 2026-06-30 14971954 frs-core:FurnitureFittings 2025-06-30 14971954 frs-core:OtherResidualIntangibleAssets 2026-06-30 14971954 frs-core:OtherResidualIntangibleAssets 2025-07-01 2026-06-30 14971954 frs-core:OtherResidualIntangibleAssets 2025-06-30 14971954 frs-core:SharePremium 2026-06-30 14971954 frs-core:ShareCapital 2026-06-30 14971954 frs-core:RetainedEarningsAccumulatedLosses 2026-06-30 14971954 frs-bus:PrivateLimitedCompanyLtd 2025-07-01 2026-06-30 14971954 frs-bus:FilletedAccounts 2025-07-01 2026-06-30 14971954 frs-bus:SmallEntities 2025-07-01 2026-06-30 14971954 frs-bus:AuditExempt-NoAccountantsReport 2025-07-01 2026-06-30 14971954 frs-bus:SmallCompaniesRegimeForAccounts 2025-07-01 2026-06-30 14971954 frs-bus:Director1 2025-07-01 2026-06-30 14971954 frs-bus:Director2 2025-07-01 2026-06-30 14971954 frs-bus:Director3 2025-07-01 2026-06-30 14971954 frs-bus:Director4 2025-07-01 2026-06-30 14971954 frs-countries:EnglandWales 2025-07-01 2026-06-30 14971954 2024-06-30 14971954 2025-06-30 14971954 2024-07-01 2025-06-30 14971954 frs-core:CurrentFinancialInstruments 2025-06-30 14971954 frs-core:SharePremium 2025-06-30 14971954 frs-core:ShareCapital 2025-06-30 14971954 frs-core:RetainedEarningsAccumulatedLosses 2025-06-30
Registered number: 14971954
TAURHYTHM THERAPIES LIMITED
Unaudited Financial Statements
For The Year Ended 30 June 2026
Katz Cunningham Ltd
TAURHYTHM THERAPIES LIMITED
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—5

Page 1
TAURHYTHM THERAPIES LIMITED
Balance Sheet
As At 30 June 2026
Balance Sheet
Registered number: 14971954

| 2026 | 2025
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Intangible Assets | 4 |  | 35,397 |  | 13,129
Tangible Assets | 5 |  | 7,745 |  | 11,617
|  |  | 43,142 |  | 24,746
CURRENT ASSETS
Debtors | 6 | 16,891 |  | 10,948 |
Cash at bank and in hand |  | 25,186 |  | 45,931 |
|  | 42,077 |  | 56,879 |
Creditors: Amounts Falling Due Within One Year | 7 | (17,598 ) |  | (9,938 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 24,479 |  | 46,941
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 67,621 |  | 71,687
NET ASSETS |  |  | 67,621 |  | 71,687
CAPITAL AND RESERVES
Called up share capital | 8 |  | 12 |  | 11
Share premium account |  |  | 354,516 |  | 173,017
Profit and Loss Account |  |  | (286,907 ) |  | (101,341 )
SHAREHOLDERS' FUNDS |  |  | 67,621 |  | 71,687

Page 1
Page 2
TAURHYTHM THERAPIES LIMITED
Balance Sheet (continued)
As At 30 June 2026
For the year ending 30 June 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Prapakaran Kanagaratnam Director
11/08/2026

The notes on pages 3 to 5 form part of these financial statements.
Page 2
Page 3
TAURHYTHM THERAPIES LIMITED
Notes to the Financial Statements
For The Year Ended 30 June 2026
Notes to the Financial Statements
1. General Information
TAURHYTHM THERAPIES LIMITED is a private company, limited by shares, incorporated in England & Wales, registered number 14971954 . The registered office is 6 Fitzjames Avenue, London, W14 0RP.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Significant judgements and estimations
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
2.3. Intangible Fixed Assets and Amortisation - Other Intangible
Other intangible assets are patents and licenses. These have not been amortised at present.
2.4. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Fixtures & Fittings | 25% per annum on straight line basis
Computer Equipment | 25% per annum on straight line basis

Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
2.5. Financial Instruments
Financial instruments
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs. Financial assets classified as receivable within one year are not amortised.
Classification of financial liabilities
...CONTINUED
Page 3
Page 4
TAURHYTHM THERAPIES LIMITED
Notes to the Financial Statements (continued)
For The Year Ended 30 June 2026
2.5. Financial Instruments - continued
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price.
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 1 (2025: 1)
1 1
4. Intangible Assets

| Other
--- | ---
| £
Cost
As at 1 July 2025 | 13,129
Additions | 22,268
As at 30 June 2026 | 35,397
Net Book Value
As at 30 June 2026 | 35,397
As at 1 July 2025 | 13,129

5. Tangible Assets

| Fixtures & Fittings
--- | ---
| £
Cost
As at 1 July 2025 | 15,490
As at 30 June 2026 | 15,490
Depreciation
As at 1 July 2025 | 3,873
Provided during the period | 3,872
As at 30 June 2026 | 7,745
Net Book Value
As at 30 June 2026 | 7,745
As at 1 July 2025 | 11,617

Page 4
Page 5
TAURHYTHM THERAPIES LIMITED
Notes to the Financial Statements (continued)
For The Year Ended 30 June 2026
6. Debtors

| 2026 |  | 2025
--- | --- | --- | ---
| £ |  | £
Due within one year
Other debtors | 16,891 |  | 10,948

7. Creditors: Amounts Falling Due Within One Year

| 2026 |  | 2025
--- | --- | --- | ---
| £ |  | £
Other creditors | 16,449 |  | 7,995
Taxation and social security | 1,149 |  | 1,943
| 17,598 |  | 9,938

8. Share Capital

| 2026 |  | 2025
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 12 |  | 11

Page 5